Eisai Co., Ltd. introduced plans to current its newest analysis findings on lecanemab, an anti-amyloid beta protofibril antibody for treating Alzheimer’s illness, on the twentieth International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders. The occasion will happen from March 17-21, 2026, in Copenhagen, Denmark, and on-line.
The firm will characteristic six shows, together with three oral shows, highlighting knowledge from a U.S. real-world long-term therapy persistence examine and outcomes in apolipoprotein E ε4 homozygous carriers. Additionally, four-year knowledge from the Clarity AD Open-Label Extension trial and a genome-wide affiliation examine on genetic variants linked to cognitive decline can be introduced as posters.
Eisai will even host an industry-sponsored symposium titled “Continue Life Their Way: Early Intervention in Alzheimer’s Disease.” The symposium will deal with the significance of early intervention and continued therapy in early Alzheimer’s illness, that includes discussions led by 4 international specialists within the area.
Lecanemab, developed in collaboration with BioArctic, is a humanized immunoglobulin gamma monoclonal antibody concentrating on amyloid-beta. It has been authorised in 53 international locations, together with the United States, China, and Japan. A subcutaneous formulation is beneath regulatory evaluation in a number of international locations, with a U.S. FDA Priority Review motion date set for May 24, 2026.
The ongoing AHEAD 3-45 Phase 3 scientific examine, carried out in partnership with the Alzheimer’s Clinical Trial Consortium and funded by the National Institute on Aging, is exploring lecanemab’s results on people with preclinical Alzheimer’s illness. Additionally, the Tau NexGen scientific examine for Dominantly Inherited Alzheimer’s Disease contains lecanemab as a foundational remedy.
Eisai and Biogen have collaborated on the event and commercialization of Alzheimer’s therapies since 2014, with Eisai main regulatory submissions globally. The firm continues to advance its Alzheimer’s illness portfolio, aiming to deal with the situation by revolutionary therapeutic approaches.